| |
Intratumoral CD4
|
Stromal CD4
|
|---|
|
HR
|
95% CI
|
P value
|
HR
|
95% CI
|
P value
|
|---|
|
Age
|
0.93
|
0.853–1.011
|
0.072
|
0.9
|
0.821–0.996
|
0.024
|
|
Dose
|
1.073
|
1.005–1.147
|
0.0073
|
1.059
|
0.994–1.13
|
0.032
|
|
HRD
|
0.92
|
0.848–1.005
|
0.053
|
0.92
|
0.841–1.007
|
0.058
|
|
Treatment
| | |
0.035
| | |
0.026
|
|
A1
|
Reference
|
Reference
|
|
A2
|
0.48
|
0.35
|
|
B1
|
2.61×10−11
|
1.92×10−11
|
|
B2
|
0.016
|
0.013
|
|
Intratumoral CD4
|
1.008
|
0.997–1.019
|
0.009
| | | |
|
Stromal CD4
| | | |
1.0023
|
1.0002–1.0044
|
0.0057
|
- A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, CI confidence interval, HR hazard ratio, Dose dose of paclitaxel in group A1, eribulin in groups A2, B1 and B2, HRD homologous recombination deficiency, pCR pathological complete response
- Statistically significant P values are shown in italics
